Developer docs
API playgroundTry for free, no card

Search company profiles

Micro Labs Usa, Inc.

Full company profile

uuid02lrdr7

Namestring
Micro Labs Usa, Inc.
Legal namestring
Micro Labs USA, Inc.
Company typeenum
Private
Founded yearint
1973
Descriptiontext

Micro Labs USA, Inc. is a privately held US pharmaceutical marketing and distribution subsidiary headquartered at 220 Davidson Avenue, Suite 402, Somerset, New Jersey. It is a wholly owned subsidiary of Micro Labs Limited, an Indian pharmaceutical company founded in 1973 that ranks among the top twenty pharmaceutical companies in India (10th in prescriptions, 20th in sales domestically). The US entity markets and distributes a portfolio of FDA-approved generic medicines — including oral solid tablets and capsules, injections, ophthalmic solutions, and oral solutions — to healthcare providers, pharmacies, and patients across cardiovascular, diabetes, ophthalmic, respiratory, neurological, and anti-infective therapeutic areas.

The company does not manufacture in the United States; all products are produced at three USFDA-approved manufacturing facilities operated by the parent in India (one in Goa, two in Bangalore). Micro Labs USA's current portfolio includes 40+ FDA-approved generic products, with 25+ additional Abbreviated New Drug Applications (ANDAs) under FDA review and a stated pipeline ambition of 10–15 new ANDA filings per year. Selected products include Atorvastatin Calcium Tablets, Dorzolamide 2% ophthalmic solution, Dorzolamide-Timolol, Metformin Oral Solution, Clobetasol 0.05% Topical Solution, Amoxicillin formulations, Brivaracetam Injection, Bimatoprost Ophthalmic Solution, and Arformoterol Tartrate Inhalation Solution. The company is vertically integrated on Dorzolamide drug substance manufacturing, which provides cost and supply-chain advantages in the ophthalmic segment.

Micro Labs USA operates a B2B go-to-market model, selling generic pharmaceuticals to healthcare providers, pharmacy chains, and institutional buyers via direct field sales and standard pharmaceutical distribution channels, with pricing determined contractually and not publicly disclosed. Revenue is generated through unit-pricing on product sales (one-time/license model). Strategic growth has been pursued through two named US partnerships: with Saptalis Pharmaceuticals LLC (announced January 2020) covering oral liquids and topicals with planned launches totaling approximately $200 million in IQVIA-measured market opportunity, and with Armas Pharmaceuticals Inc. (announced May 2019) targeting multi-source injectables. Headcount at the US subsidiary is 11–50 employees, consistent with a lean marketing/distribution wrapper around the parent's much larger manufacturing and R&D infrastructure.

Short descriptiontext

Micro Labs USA, Inc. is the US marketing and distribution arm of Indian generics manufacturer Micro Labs Limited, selling FDA-approved generic oral, injectable, ophthalmic, and oral-solution medicines to US healthcare providers and pharmacies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSomerset, United States
HQ citystring
Somerset
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, oral solid tablets, ophthalmic solutions, generic injectables, ANDA filings
Industry2 codes
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIABAC
Sterile Injectable Generics
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from manufacturing and selling FDA-approved generic pharmaceutical products including oral tablets, capsules, injections, ophthalmic solutions, and oral solutions to healthcare providers and through pharmaceutical distribution channels

microlabsusa.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Generic pharmaceutical products sold to healthcare providers and pharmacies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Pricing determined through contracts with healthcare providers and pharmacy chains; specific pricing not publicly disclosed on website

microlabsusa.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Micro Labs USA markets and distributes a portfolio of FDA-approved generic pharmaceutical products in the U.S. market, including oral solid tablets and capsules, injectable medications, ophthalmic solutions, and oral solutions. Products span cardiovascular, antibiotic, anti-infective, respiratory, neurological, ophthalmic, and diabetes therapeutic categories and are manufactured in three USFDA-approved facilities operated by parent Micro Labs Limited in India.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • $8.5 billion US Ophthalmic market presence established with launch of glaucoma drugs (Dorzolamide and Dorzolamide-Timolol)
+1 more record
Product overview1 text field

Micro Labs USA is a pharmaceutical company marketing a portfolio of FDA-approved generic medications across multiple dosage forms. The company offers oral solid tablets and capsules, injections, ophthalmic solutions, and oral solutions. Key products include cardiovascular medications (Atorvastatin Calcium, Amlodipine/Olmesartan), antibiotics (Amoxicillin products), respiratory treatments (Arformoterol), neurological medications (Brivaracetam, Aspirin/Dipyridamole), ophthalmic products (Bimatoprost, Dorzolamide), and diabetes treatments (Metformin). These products are manufactured in three USFDA-approved facilities in India (Goa and Bangalore) and distributed in the US market.

Product and service14 records
1Acetazolamide Extended-Release Capsules
CategoryGeneric Pharmaceutical Product
Description

Extended-release capsules for treatment of certain conditions. Generic equivalent of Diamox Sequels.

2Amlodipine Besylate and Olmesartan Medoxomil Tablets
CategoryGeneric Pharmaceutical Product
Description

Combination medication tablets for cardiovascular treatment. Generic equivalent of Azor.

3Amoxicillin and Clavulanate Potassium for Oral Suspension, USP
CategoryGeneric Pharmaceutical Product
Description

Antibiotic oral suspension in two strengths (200 mg/28.5 mg per 5 mL and 400 mg/57 mg per 5 mL) for treating bacterial infections.

4Amoxicillin and Clavulanate Potassium Tablets, USP
CategoryGeneric Pharmaceutical Product
Description

Antibiotic tablets available in multiple strengths (250/125 mg, 500/125 mg, 875/125 mg). Generic equivalent of Augmentin.

5Amoxicillin Capsules, USP
CategoryGeneric Pharmaceutical Product
Description

Antibiotic capsules in 500 mg strength. Generic equivalent of Amoxil.

6Arformoterol Tartrate Inhalation Solution
CategoryGeneric Pharmaceutical Product
Description

Inhalation solution for respiratory treatment (15 mcg/2 mL, 30 vials). Generic equivalent of Brovana.

7Aspirin and Extended-Release Dipyridamole Capsules
CategoryGeneric Pharmaceutical Product
Description

Extended-release combination capsules (25 mg/200 mg) for antiplatelet therapy. Generic equivalent of Aggrenox.

8Atorvastatin Calcium Tablets
CategoryGeneric Pharmaceutical Product
Description

Cholesterol management tablets available in 10 mg, 20 mg, 40 mg, and 80 mg strengths. Generic equivalent of Lipitor.

9Bimatoprost Ophthalmic Solution
CategoryGeneric Pharmaceutical Product
Description

Ophthalmic solution (0.03%) for glaucoma treatment available in 2.5 mL, 5 mL, and 7.5 mL bottles. Generic equivalent of Lumigan.

10Brivaracetam Injection
CategoryGeneric Pharmaceutical Product
Description

Antiepileptic injection (50 mg/5 mL). Generic equivalent of Briviact.

11Dorzolamide 2% Ophthalmic Solution
CategoryGeneric Pharmaceutical Product
Description

Ophthalmic solution for glaucoma treatment. Company is vertically integrated with Dorzolamide drug substance.

12Dorzolamide-Timolol 22.3-6.8 mg/mL Ophthalmic Solution
CategoryGeneric Pharmaceutical Product
Description

Combination ophthalmic solution for glaucoma treatment.

13Metformin Oral Solution 500 mg/5mL
CategoryGeneric Pharmaceutical Product
Description

Oral solution (500 mg/5mL) indicated as adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Only generic version of Riomet.

14Clobetasol 0.05% Topical Solution
CategoryGeneric Pharmaceutical Product
Description

Topical solution for treatment of psoriasis and dermatitis. Generic equivalent of Clobex.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-24
Description

Strategic collaboration between Micro Labs USA and Saptalis Pharmaceuticals to launch single-source and multisource generics in the United States. First product was Clobetasol 0.05% topical solution (generic of Clobetasol). The partnership covers oral liquid and topical products with planned launches totaling $200 million in market size (per IQVIA data). Saptalis brings formulation development expertise in liquid and semi-solid dosage forms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-28
Description

Strategic collaboration to bring select multisource injectable products to the U.S. market. This partnership expands Micro Labs' presence in the injectable generic pharmaceuticals segment. First products under this collaboration were select multisource injectable medications.

Strategic tierFlagshipTypeOthers
Description

Micro Labs USA, Inc. is a wholly owned subsidiary of Micro Labs Limited, India. Parent company founded in 1973, ranked among top 20 pharmaceutical companies in India (10th among prescriptions and 20th in sales in India local market). Provides manufacturing facilities (Goa and Bangalore), R&D capabilities, and corporate oversight.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Endo International
TypeBroad incumbent
Description

US-based specialty and generics pharmaceutical company with overlapping generic injectable and oral solid portfolios. Comparable in the generic injectables and specialty generics segments, though broader in branded specialty.

TypeDirect peer
Description

Indian-headquartered generic pharmaceutical company with a US-focused subsidiary. Comparable product mix (oral solids, injectables, ophthalmics) and ANDA-driven US growth strategy.

TypeDirect peer
Description

US arm of Aurobindo Pharma, one of India's largest generic manufacturers. Directly comparable as an Indian-headquartered generic company with broad US generic portfolio across oral solids, injectables, and ophthalmics, with deep ANDA pipeline and USFDA-approved Indian facilities.

4Sandoz (Novartis)
TypeBroad incumbent
Description

Global generic and biosimilar leader spun out of Novartis. Overlaps with Micro Labs USA across generic oral solids, injectables, and ophthalmics, but operates at vastly larger scale and with broader geographic footprint.

TypeDirect peer
Description

US generics subsidiary of Hetero Labs (India), focused exclusively on the US generic market. Closely comparable scale and operational model to Micro Labs USA, with similar ANDA-driven US generic strategy.

TypeDirect peer
Description

India-based global generic pharmaceutical manufacturer with significant US operations. Comparable as a vertically integrated Indian generic player with broad US ANDA pipeline, injectables, and ophthalmics portfolio.

TypeDirect peer
Description

India-based generic and specialty pharmaceutical company with a US subsidiary marketing generic oral solids and injectables. Similar model of Indian manufacturing feeding US distribution.

TypeBroad incumbent
Description

World's largest generic pharmaceutical manufacturer, with a US-dominant generics business across all major therapeutic categories and dosage forms. Comparable portfolio breadth but at much larger scale and with broader specialty pharma exposure.

TypeDirect peer
Description

Canadian-headquartered generic pharmaceutical manufacturer with major US operations. Comparable as a non-US-headquartered generic player serving the US market across oral solids, injectables, and ophthalmics.

TypeDirect peer
Description

US subsidiary of India's Zydus Cadila, with comparable product breadth across cardiovascular, anti-infective, ophthalmic and other generic categories. Similar business model of leveraging parent manufacturing for US market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micro Labs Usa, Inc.

Generic Pharmaceuticalsmicrolabsusa.com

Micro Labs USA, Inc. is the US marketing and distribution arm of Indian generics manufacturer Micro Labs Limited, selling FDA-approved generic oral, injectable, ophthalmic, and oral-solution medicines to US healthcare providers and pharmacies.

What Micro Labs Usa, Inc. does

Micro Labs USA, Inc. is a privately held US pharmaceutical marketing and distribution subsidiary headquartered at 220 Davidson Avenue, Suite 402, Somerset, New Jersey. It is a wholly owned subsidiary of Micro Labs Limited, an Indian pharmaceutical company founded in 1973 that ranks among the top twenty pharmaceutical companies in India (10th in prescriptions, 20th in sales domestically). The US entity markets and distributes a portfolio of FDA-approved generic medicines — including oral solid tablets and capsules, injections, ophthalmic solutions, and oral solutions — to healthcare providers, pharmacies, and patients across cardiovascular, diabetes, ophthalmic, respiratory, neurological, and anti-infective therapeutic areas.

The company does not manufacture in the United States; all products are produced at three USFDA-approved manufacturing facilities operated by the parent in India (one in Goa, two in Bangalore). Micro Labs USA's current portfolio includes 40+ FDA-approved generic products, with 25+ additional Abbreviated New Drug Applications (ANDAs) under FDA review and a stated pipeline ambition of 10–15 new ANDA filings per year. Selected products include Atorvastatin Calcium Tablets, Dorzolamide 2% ophthalmic solution, Dorzolamide-Timolol, Metformin Oral Solution, Clobetasol 0.05% Topical Solution, Amoxicillin formulations, Brivaracetam Injection, Bimatoprost Ophthalmic Solution, and Arformoterol Tartrate Inhalation Solution. The company is vertically integrated on Dorzolamide drug substance manufacturing, which provides cost and supply-chain advantages in the ophthalmic segment.

Micro Labs USA operates a B2B go-to-market model, selling generic pharmaceuticals to healthcare providers, pharmacy chains, and institutional buyers via direct field sales and standard pharmaceutical distribution channels, with pricing determined contractually and not publicly disclosed. Revenue is generated through unit-pricing on product sales (one-time/license model). Strategic growth has been pursued through two named US partnerships: with Saptalis Pharmaceuticals LLC (announced January 2020) covering oral liquids and topicals with planned launches totaling approximately $200 million in IQVIA-measured market opportunity, and with Armas Pharmaceuticals Inc. (announced May 2019) targeting multi-source injectables. Headcount at the US subsidiary is 11–50 employees, consistent with a lean marketing/distribution wrapper around the parent's much larger manufacturing and R&D infrastructure.

Micro Labs Usa, Inc. firmographics

Firmographics
Name
Micro Labs Usa, Inc.
Legal name
Micro Labs USA, Inc.
Website
https://microlabsusa.com
Company type
Private
Founded year
1973
Operating status
Operating
Headcount range
11–50 employees
Short description
Micro Labs USA, Inc. is the US marketing and distribution arm of Indian generics manufacturer Micro Labs Limited, selling FDA-approved generic oral, injectable, ophthalmic, and oral-solution medicines to US healthcare providers and pharmacies.
Ownership category
akta.pro rank

Micro Labs Usa, Inc. industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIABAL
Generic Hospital & Institutional Products
SECONDARYHLAIABAC
Sterile Injectable Generics

Keywords

  • Generic pharmaceuticals
  • Oral solid tablets
  • Ophthalmic solutions
  • Generic injectables
  • ANDA filings

Where Micro Labs Usa, Inc. is headquartered

Location

Headquarters

HQ city
Somerset
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Micro Labs Usa, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic Pharmaceutical Product Sales: Revenue generated from manufacturing and selling FDA-approved generic pharmaceutical products including oral tablets, capsules, injections, ophthalmic solutions, and oral solutions to healthcare providers and through pharmaceutical distribution channels

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGeneric pharmaceutical products sold to healthcare providers and pharmacies

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Micro Labs Usa, Inc. product offering

Product offering

Core offering

Micro Labs USA markets and distributes a portfolio of FDA-approved generic pharmaceutical products in the U.S. market, including oral solid tablets and capsules, injectable medications, ophthalmic solutions, and oral solutions. Products span cardiovascular, antibiotic, anti-infective, respiratory, neurological, ophthalmic, and diabetes therapeutic categories and are manufactured in three USFDA-approved facilities operated by parent Micro Labs Limited in India.

Product overview

Micro Labs USA is a pharmaceutical company marketing a portfolio of FDA-approved generic medications across multiple dosage forms. The company offers oral solid tablets and capsules, injections, ophthalmic solutions, and oral solutions. Key products include cardiovascular medications (Atorvastatin Calcium, Amlodipine/Olmesartan), antibiotics (Amoxicillin products), respiratory treatments (Arformoterol), neurological medications (Brivaracetam, Aspirin/Dipyridamole), ophthalmic products (Bimatoprost, Dorzolamide), and diabetes treatments (Metformin). These products are manufactured in three USFDA-approved facilities in India (Goa and Bangalore) and distributed in the US market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Acetazolamide Extended-Release Capsules Extended-release capsules for treatment of certain conditions. Generic equivalent of Diamox Sequels.
  • Amlodipine Besylate and Olmesartan Medoxomil Tablets Combination medication tablets for cardiovascular treatment. Generic equivalent of Azor.
  • Amoxicillin and Clavulanate Potassium for Oral Suspension, USP Antibiotic oral suspension in two strengths (200 mg/28.5 mg per 5 mL and 400 mg/57 mg per 5 mL) for treating bacterial infections.
  • Amoxicillin and Clavulanate Potassium Tablets, USP Antibiotic tablets available in multiple strengths (250/125 mg, 500/125 mg, 875/125 mg). Generic equivalent of Augmentin.
  • Amoxicillin Capsules, USP Antibiotic capsules in 500 mg strength. Generic equivalent of Amoxil.
  • Arformoterol Tartrate Inhalation Solution Inhalation solution for respiratory treatment (15 mcg/2 mL, 30 vials). Generic equivalent of Brovana.
  • Aspirin and Extended-Release Dipyridamole Capsules Extended-release combination capsules (25 mg/200 mg) for antiplatelet therapy. Generic equivalent of Aggrenox.
  • Atorvastatin Calcium Tablets Cholesterol management tablets available in 10 mg, 20 mg, 40 mg, and 80 mg strengths. Generic equivalent of Lipitor.
  • Bimatoprost Ophthalmic Solution Ophthalmic solution (0.03%) for glaucoma treatment available in 2.5 mL, 5 mL, and 7.5 mL bottles. Generic equivalent of Lumigan.
  • Brivaracetam Injection Antiepileptic injection (50 mg/5 mL). Generic equivalent of Briviact.
  • Dorzolamide 2% Ophthalmic Solution Ophthalmic solution for glaucoma treatment. Company is vertically integrated with Dorzolamide drug substance.
  • Dorzolamide-Timolol 22.3-6.8 mg/mL Ophthalmic Solution Combination ophthalmic solution for glaucoma treatment.
  • Metformin Oral Solution 500 mg/5mL Oral solution (500 mg/5mL) indicated as adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes. Only generic version of Riomet.
  • Clobetasol 0.05% Topical Solution Topical solution for treatment of psoriasis and dermatitis. Generic equivalent of Clobex.

Quantifiable outcome

  • $8.5 billion US Ophthalmic market presence established with launch of glaucoma drugs (Dorzolamide and Dorzolamide-Timolol)
  • +1 more outcomes

Companies that use Micro Labs Usa, Inc.

Customer profile

Segments1 record

Ideal customer profiles1 record

Micro Labs Usa, Inc. technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Micro Labs Usa, Inc. partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • Saptalis Pharmaceuticals LLCcoreStrategic or Co-development Partner · 24 January 2020Strategic collaboration between Micro Labs USA and Saptalis Pharmaceuticals to launch single-source and multisource generics in the United States. First product was Clobetasol 0.05% topical solution (generic of Clobetasol). The partnership covers oral liquid and topical products with planned launches totaling $200 million in market size (per IQVIA data). Saptalis brings formulation development expertise in liquid and semi-solid dosage forms.
  • Armas Pharmaceuticals Inc.coreStrategic or Co-development Partner · 28 May 2019Strategic collaboration to bring select multisource injectable products to the U.S. market. This partnership expands Micro Labs' presence in the injectable generic pharmaceuticals segment. First products under this collaboration were select multisource injectable medications.
  • Micro Labs LimitedflagshipOthersMicro Labs USA, Inc. is a wholly owned subsidiary of Micro Labs Limited, India. Parent company founded in 1973, ranked among top 20 pharmaceutical companies in India (10th among prescriptions and 20th in sales in India local market). Provides manufacturing facilities (Goa and Bangalore), R&D capabilities, and corporate oversight.

Scale indicators5 records

Recent moves5 records

Expansion highlights6 records

Micro Labs Usa, Inc. competitors and assessment

Company assessment

Broad incumbents

  • Endo International: US-based specialty and generics pharmaceutical company with overlapping generic injectable and oral solid portfolios. Comparable in the generic injectables and specialty generics segments, though broader in branded specialty.
  • Sandoz (Novartis): Global generic and biosimilar leader spun out of Novartis. Overlaps with Micro Labs USA across generic oral solids, injectables, and ophthalmics, but operates at vastly larger scale and with broader geographic footprint.
  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer, with a US-dominant generics business across all major therapeutic categories and dosage forms. Comparable portfolio breadth but at much larger scale and with broader specialty pharma exposure.

Direct peers

  • Lupin Pharmaceuticals: Indian-headquartered generic pharmaceutical company with a US-focused subsidiary. Comparable product mix (oral solids, injectables, ophthalmics) and ANDA-driven US growth strategy.
  • Aurobindo Pharma USA: US arm of Aurobindo Pharma, one of India's largest generic manufacturers. Directly comparable as an Indian-headquartered generic company with broad US generic portfolio across oral solids, injectables, and ophthalmics, with deep ANDA pipeline and USFDA-approved Indian facilities.
  • Camber Pharmaceuticals: US generics subsidiary of Hetero Labs (India), focused exclusively on the US generic market. Closely comparable scale and operational model to Micro Labs USA, with similar ANDA-driven US generic strategy.
  • Dr. Reddy's Laboratories: India-based global generic pharmaceutical manufacturer with significant US operations. Comparable as a vertically integrated Indian generic player with broad US ANDA pipeline, injectables, and ophthalmics portfolio.
  • Glenmark Pharmaceuticals: India-based generic and specialty pharmaceutical company with a US subsidiary marketing generic oral solids and injectables. Similar model of Indian manufacturing feeding US distribution.
  • Apotex Corp. Canadian-headquartered generic pharmaceutical manufacturer with major US operations. Comparable as a non-US-headquartered generic player serving the US market across oral solids, injectables, and ophthalmics.
  • Zydus Pharmaceuticals USA: US subsidiary of India's Zydus Cadila, with comparable product breadth across cardiovascular, anti-infective, ophthalmic and other generic categories. Similar business model of leveraging parent manufacturing for US market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Micro Labs Usa, Inc. social profiles

Digital presence

Micro Labs Usa, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micro Labs Usa, Inc. leadership team

Management profile

Number of profiles

Profiles1 record

Micro Labs Usa, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micro Labs Usa, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micro Labs Usa, Inc.

What does Micro Labs Usa, Inc. do?

Micro Labs USA markets and distributes a portfolio of FDA-approved generic pharmaceutical products in the U.S. market, including oral solid tablets and capsules, injectable medications, ophthalmic solutions, and oral solutions. Products span cardiovascular, antibiotic, anti-infective, respiratory, neurological, ophthalmic, and diabetes therapeutic categories and are manufactured in three USFDA-approved facilities operated by parent Micro Labs Limited in India.

Is Micro Labs Usa, Inc. a public or private company?

Micro Labs Usa, Inc. is a private company. It is classified as corporate owned and is currently operating.

When was Micro Labs Usa, Inc. founded?

Micro Labs Usa, Inc. was founded in 1973. It employs 11 to 50 people.

Where is Micro Labs Usa, Inc. based?

Micro Labs Usa, Inc. is headquartered in Somerset, United States, in the North America region.

How does Micro Labs Usa, Inc. make money?

One revenue line is on record: generic Pharmaceutical Product Sales.

Who are Micro Labs Usa, Inc.'s main competitors?

Broad incumbents on record are Endo International, Sandoz (Novartis) and Teva Pharmaceutical Industries. Direct peers are Lupin Pharmaceuticals, Aurobindo Pharma USA, Camber Pharmaceuticals, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Apotex Corp. and Zydus Pharmaceuticals USA.

Does Micro Labs Usa, Inc. have an API?

No public API is recorded for Micro Labs Usa, Inc..

What industry is Micro Labs Usa, Inc. in?

Micro Labs Usa, Inc.'s product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIABAC, Sterile Injectable Generics. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGingivitis Treatment Market to hit US$ 2.90Billion by 2033 | Top 5 Companies are Micro Labs USA, Inc, GlaxoSmithKline, Zydus Cadila, and Bausch Health Companies Inc, Dr. Reddy's Laboratories LtdThe global gingivitis treatment market is projected to grow from US$1.71B in 2024 to US$2.90B by 2033, a CAGR of 5.5%. North America holds the largest revenue share at 45.5% in 2024, while Asia Pacific is the fastest-growing region at 7.5% CAGR. Key players include Micro Labs USA, GlaxoSmithKline, and Dr. Reddy's Laboratories.Drug Store NewsMicro Labs, Saptalis ink generics deal, launch first productMicro Labs USA and Saptalis Pharmaceuticals have entered a strategic collaboration to launch single-source and multisource generic drugs in the United States, starting with Clobex topical solution. The companies plan to introduce additional products targeting a market size of $200 million during the second and third quarters of 2020.PR NewswireNew Products launched by Micro Labs USA IncMicro Labs USA announced the launch of Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL in the US ophthalmic market. The company cited a $8.5 billion market and approximately 320 million annual applications, with additional products under FDA review.BioSpaceMicro Labs USA Inc and Saptalis Pharmaceuticals LLC Announce Launch of Metformin Oral Solution (500 mg/5mL in two presentations 118mL and 473mL)Micro Labs USA Inc and Saptalis Pharmaceuticals LLC announced the launch of a generic Metformin Oral Solution in the US market, marking their second collaboration within three months. The FDA granted Saptalis 180-day marketing exclusivity after it successfully challenged the patent for the brand-name product Riomet. This launch provides an affordable liquid formulation for patients with type 2 diabetes who have difficulty swallowing.PR NewswireFDA approves first generics of EliquisThe U.S. Food and Drug Administration approved the first generic versions of Eliquis (apixaban) tablets from Micro Labs Limited and Mylan Pharmaceuticals Inc. This approval marks a significant milestone as the first generic direct oral anticoagulants, aiming to improve patient access to lower-cost medicines for stroke prevention and blood clot treatment. The move aligns with the FDA's Drug Competition Action Plan to promote generic competition.PR NewswireArmas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. MarketArmas Pharmaceuticals Inc. and Micro Labs USA, Inc. announced a strategic collaboration to bring select multisource injectable products to the U.S. market, with the first product being Diphenhydramine Injection 50mg/1mL. The drug has been on the FDA Drug Shortage list since September 2018 and is slated for launch in May 2019, with additional products planned for Q2 2019. The combined market size of these products totals $100 million annually, according to IMS data.